SCHEMBL2600057

SCHEMBL2600057

COc1ncnc2c1CCN2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 2/20 0.49
NNMT P40261 2/20 0.41
ALDH1A1 P00352 1/20 0.37
PDPK1 O15530 1/20 0.37
HTR2C P28335 1/20 0.35
MKNK1 Q9BUB5 1/20 0.34
KDR P35968 5/20 0.34
AKT1S1 Q96B36 4/20 0.33
CHEK1 O14757 2/20 0.33
DAPK3 O43293 2/20 0.33
PRKD3 O94806 2/20 0.33
MAP4K4 O95819 2/20 0.33
RET P07949 2/20 0.33
FGFR1 P11362 2/20 0.33
FLT1 P17948 2/20 0.33
LTK P29376 2/20 0.33
GRK5 P34947 2/20 0.33
CSNK1A1 P48729 2/20 0.33
CDK8 P49336 2/20 0.33
CDK7 P50613 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30159359 0.75 DRD1 (0.49) DRD1NNMTMKNK1KDRAKT1S1
SCHEMBL795294 0.75 DRD1 (0.49) DRD1NNMTMKNK1KDRAKT1S1
SCHEMBL29201815 0.72 NNMT (0.45) DRD1NNMTMKNK1KDRAKT1S1
SCHEMBL3507179 0.72 EGFR (0.44) DRD1NNMTRETLCKMET
SCHEMBL29870801 0.71 CHRM3 (0.41) ALDH1A1PDPK1HTR2CKDR
SCHEMBL6764925 0.71 CHRM3 (0.41) ALDH1A1PDPK1HTR2CKDR
SCHEMBL22677334 0.71 NNMT (0.46) DRD1NNMTALDH1A1MKNK1KDR
SCHEMBL29487134 0.71 NNMT (0.44) DRD1NNMTHTR2CMKNK1KDR
SCHEMBL30159408 0.71 KDR (0.50) DRD1NNMTMKNK1KDRAKT1S1
SCHEMBL3803152 0.71 NNMT (0.44) DRD1NNMTHTR2CMKNK1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158636-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2012-04-17 US disclosed
US-20090286782-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-20090286783-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286783-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR BRAF, PRKACA, RAF1 DRD1 4210/4885NNMT 2326/4885ALDH1A1 1669/4885
US-20090286782-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PRKDC, PRKACA, PRKACG DRD1 4606/4885NNMT 663/4885ALDH1A1 3699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.